OrbusNeich has received approval from Tawain’s Department of Health to market the Genous bio-engineered stent.
The Genous stent is coated with an antibody to capture a patient’s endothelial progenitor cells (EPCs) circulating in the bloodstream, according to the Hong Kong-based OrbusNeich. When attracted to the inner surface of the Genous stent, EPCs have been shown to quickly form a healthy layer of endothelium that minimizes stent restenosis and provides protection against stent thrombosis.
The company said that an estimated 20,000 coronary angioplasty procedures will be performed in Taiwan in 2008, 60 percent of which are expected to involve the use of drug-eluting stents.
“The introduction of our pro-healing stent to the Taiwanese market is an important step for our company as we expand our presence in the Asia-Pacific region,” Teddy Chien, OrbusNeich’s chairman.